Mary McCormack, PhD, MBBS, on Locally Advanced Cervical Cancer: Results From the INTERLACE Trial
SGO 2024 Annual Meeting on Womens Cancer
Mary McCormack, PhD, MBBS, of University College London Hospitals, NHS Foundation Trust, discusses the global health issue of cervical cancer and a way forward. Phase III findings from the GCIG INTERLACE trial showed that induction chemotherapy with weekly paclitaxel and carboplatin before chemoradiation not only improved survival outcomes, it is feasible across diverse health-care settings and may be considered a new standard in locally advanced cervical cancer.
The ASCO Post Staff
Mansoor R. Mirza, MD, of Copenhagen University Hospital, discusses follow-up results from the RUBY trial, showing that, for patients with primary advanced or recurrent endometrial cancer, dostarlimab-gxly plus chemotherapy followed by dostarlimab-gxly plus niraparib improved progression-free survival in the overall and subgroup populations. Given the potential role for PARP inhibitor maintenance, the study is ongoing to obtain overall survival data.
The ASCO Post Staff
Brian M. Slomovitz, MD, of Mount Sinai Medical Center, Miami Beach, discusses additional phase III data from the innovaTV 301 trial, which showed that in patients with previously treated recurrent or metastatic cervical cancer, tisotumab vedotin-tftv was more efficacious than chemotherapy as second- or third-line treatment. According to Dr. Slomovitz, this agent may be considered a potential new standard of care in this population.
The ASCO Post Staff
Matthew A. Powell, MD, of the Washington University School of Medicine, discusses phase III findings from the RUBY trial, which shows dostarlimab-gxly plus chemotherapy improves overall survival in patients with primary advanced or recurrent endometrial cancer, regardless of mismatch repair status. According to Dr. Powell, this regimen could become a new standard of care.
The ASCO Post Staff
Anne Knisely, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings showing that patients with ovarian cancer who undergo second-look laparoscopy and are found to have measurable residual disease (MRD) as well as circulating tumor DNA (ctDNA) after front-line therapy have a particularly poor prognosis. These data suggest treatments should be individualized by stratifying risk, and front-line clinical trials of ovarian cancer should use MRD as a surrogate endpoint.
The ASCO Post Staff
Ana Oaknin, MD, PhD, of Spain’s Vall d’Hebron University Hospital, discusses phase III findings from the BEATcc trial, showing that adding atezolizumab to a standard bevacizumab-plus-platinum regimen for patients with metastatic, persistent, or recurrent cervical cancer significantly improves survival outcomes and may be considered a new first-line treatment option.
